Trial · NCT04475588
Results by group97
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 97
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| One-month Mortality Rate Between the Two Arms | Arm A - Itolizumab + BSC | 0 | participants | ||
| One-month Mortality Rate Between the Two Arms | Arm B - Best Supportive Care (BSC) | 3 | participants | ||
| Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2 | Arm A - Itolizumab + BSC | Day 7 | 17 | participants | |
| Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2 | Arm B - Best Supportive Care (BSC) | Day 7 | 5 | participants | |
| Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2 | Arm A - Itolizumab + BSC | Day 14 | 19 | participants | |
| Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2 | Arm B - Best Supportive Care (BSC) | Day 14 | 7 | participants | |
| Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2 | Arm A - Itolizumab + BSC | Day 21 | 20 | participants | |
| Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2 | Arm B - Best Supportive Care (BSC) | Day 21 | 7 | participants | |
| Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2 | Arm A - Itolizumab + BSC | Day 30/EOS | 20 | participants | |
| Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2 | Arm B - Best Supportive Care (BSC) | Day 30/EOS | 7 | participants | |
| Endo-tracheal Intubation/Invasive Mechanical Ventilation (IMV) | Arm A - Itolizumab + BSC | 0 | participants | ||
| Endo-tracheal Intubation/Invasive Mechanical Ventilation (IMV) | Arm B - Best Supportive Care (BSC) | 2 | participants | ||
| Reduction in Proportion of Patients on Non-invasive Ventilation | Arm A - Itolizumab + BSC | Baseline (Day 1) | 5 | participants | |
| Reduction in Proportion of Patients on Non-invasive Ventilation | Arm B - Best Supportive Care (BSC) | Baseline (Day 1) | 4 | participants | |
| Reduction in Proportion of Patients on Non-invasive Ventilation | Arm A - Itolizumab + BSC | Day 7 | 0 | participants | |
| Reduction in Proportion of Patients on Non-invasive Ventilation | Arm B - Best Supportive Care (BSC) | Day 7 | 0 | participants | |
| Reduction in Proportion of Patients on Non-invasive Ventilation | Arm A - Itolizumab + BSC | Day 14 | 5 | participants | |
| Reduction in Proportion of Patients on Non-invasive Ventilation | Arm B - Best Supportive Care (BSC) | Day 14 | 1 | participants | |
| Reduction in Proportion of Patients on Non-invasive Ventilation | Arm A - Itolizumab + BSC | Day 21 | 5 | participants | |
| Reduction in Proportion of Patients on Non-invasive Ventilation | Arm B - Best Supportive Care (BSC) | Day 21 | 1 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04475588/results